Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Current Assets (2016 - 2025)

Traws Pharma (TRAW) has disclosed Current Assets for 14 consecutive years, with $9.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 7.87% to $9.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.6 million, a 7.87% increase, with the full-year FY2024 number at $25.0 million, up 10.11% from a year prior.
  • Current Assets was $9.6 million for Q3 2025 at Traws Pharma, down from $15.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $59.9 million in Q3 2021 to a low of $8.9 million in Q3 2024.
  • A 5-year average of $32.7 million and a median of $30.4 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 180.18% in 2021, then plummeted 66.97% in 2024.
  • Traws Pharma's Current Assets stood at $55.4 million in 2021, then fell by 29.01% to $39.3 million in 2022, then crashed by 42.41% to $22.7 million in 2023, then increased by 10.11% to $25.0 million in 2024, then plummeted by 61.42% to $9.6 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Current Assets are $9.6 million (Q3 2025), $15.4 million (Q2 2025), and $18.9 million (Q1 2025).